Court Confirms Seagen Damages Award in Enhertu Patent Dispute

A federal court in Texas confirmed that Daiichi Sankyo and AstraZeneca’s drug Enhertu (fam-trastuzumab deruxtecan-nxki) willfully infringed on Seagen’s patent related to the drug.

After confirming the jury verdict from April, the U.S. district court in Texas ruled that Seagen will be awarded $41.8 million in damages but that there would be no increase.

The court also did not address whether to award a royalty on future sales of Enhertu until Seagen’s patent expires in 2024.

Daiichi Sankyo said it will continue to vigorously defend its rights and explore post-trial motions and remedies to contest the judgment and damages awarded to Seagen.